华福证券 其他电源设备Ⅲ 2025 年 05 月 06 日 公 司 研 究 海博思创（688411.SH） 海外拓张加速+在手订单充足支撑增长，25 年业 绩有望放量 储能业务稳健发展，毛利率优于同业。公司 2024 年实现储能业务收入 81.93 亿元，实现销量 11.82GWh，对应单价 0.69 元/Wh，毛利率 18.22%优 于同业。公司毛利率较优主要由于：①公司投标重视利润，不以低价内卷 为竞争策略；②公司重视技术降本，通常集采项目从中标到实施存在 3-9 个月的周期，为具体项目进一步技术降本存在空间；③公司作为头部企业， 采购具备规模化集采优势；④公司生产计划注重结合项目运输半径、规模 化制造等因素，进一步降低生产成本。地域分布方面，公司 2024 年海外收 入占比达 6.51%，海外业务实现突破。 四大区域重点布局，海外业务有望发力。公司 2024 年实现境外收入 5.39 亿元，占总营业收入比例达 6.51%。公司重点布局欧洲、北美、中东、 亚太四大区域，2024 年已经在欧洲区域交付超过 300MWh 储能系统集成项 目，公司预计欧洲市场将迎来爆发式增长，东南亚市场拓展也取得突破， 202 ...

赛伍技术（603212.SH）：光伏材料 盈利下滑，持续推进产品结构优化 ——2024 年年报及 25 年一季报业绩点评 财务要点：公司 24 年全年实现营业收入 30.04 亿，同比下滑 27.89%，实现归 母净利-2.85 亿元，同比下滑 375.0%。25 年 Q1 实现营业收入 6.43 亿元，同 比下滑 27.35%，实现归母净利-0.33 亿元，同比下滑 216.13%。 胶膜、背板盈利能力下滑致业绩表现不佳。24 年公司营收下滑主要原因为背 板、胶膜单价分别下降 24.92%、32.86%；同时 TOPCon 组件双玻化对背板 市场需求产生冲击，公司 2024 年背板出货量减少 35.37%。公司归母净利首 次出现亏损，主要原因为 1）光伏背板、胶膜等产品因行业同质化竞争导致毛 利率下降，从第三季度开始出现亏损；2）原材料及主营产品价格下滑，公司 基于审慎原则，计提资产减值 8,771 万元，应收账款等信用减值 1.12 亿元。 25 年一季度随着行业抢装，公司毛利率从负转正修复至 2.67%，归母净利环 比减亏 82.5%。 光伏材料板块将继续优化产品结构。随着 TOPCon、HJT、XBC ...

2025 年 5 月 6 日 证券研究报告/公司研究 医疗研发外包/医疗服务/医药生物 利润端阶段性承压，行业呈现初步复苏迹象 事件： 公司发布2024年年报和2025年一季报：2024年公司实现营收8.04亿元， 同比增长5.75%；归母净利润1.06亿元，同比下滑21.01%；扣非归母净 利润为0.83亿元，同比下滑26.88%。2025年第一季度，公司实现营收1.76 亿元，同比下滑4.37%；归母净利润0.07亿元，同比下滑67.32%；扣非 归母净利润0.05亿元，同比下滑75.34%。 当前股价 27.51 元 投资评级 增持 评级变动 下调 总股本 0.61 亿股 流通股本 0.47 亿股 总市值 16.78 亿元 事件点评： ◆受订单价格和成本端影响，公司利润端承压。2024年公司销售毛利率 为24.38%，同比下滑6.03个百分点，主要系公司业务需求储备了业务人 员，增加的业务人员使得营业成本相应增加所致，2024年公司销售成本 率为75.62%，同比增加6.09个百分点。费用率方面，2024年，公司管理、 销售、研发、财务费用率分别为5.45%/1.07%/4.46%/-0.33%，较为稳 ...

Investment Rating - The report assigns an "Accumulate" rating for the company, indicating a potential stock price increase of 5% to 15% over the next six months [4]. Core Insights - The company has shown steady growth in its core business, particularly in the intelligent transmission sector, with a comprehensive product lineup including harmonic reducers, RV reducers, and planetary reducers. This positions the company well to meet diverse customer needs and enhance integration efficiency [9]. - The humanoid robot business is progressing well, with plans to invest 200 million in a new precision component production line, aiming to capitalize on the expected growth in the humanoid robot market [9]. - Financial forecasts predict the company's net profit attributable to shareholders will reach 0.85 billion, 1.09 billion, and 1.33 billion for the years 2025 to 2027, with corresponding PE ratios of 161.75, 126.41, and 103.30 [9]. Financial Summary - For 2023, the company reported revenue of 1,086 million, with a year-on-year growth of 20.99%. However, a decline of 10.10% is expected in 2024, followed by a recovery with projected growth rates of 13.01%, 12.88%, and 12.96% for 2025, 2026, and 2027 respectively [2]. - The net profit attributable to the parent company for 2023 was 73 million, with a slight increase of 10.22%. The forecast for 2024 shows a minor decline of 0.82%, but significant growth is expected in the following years [2]. - The earnings per share (EPS) for 2023 was 0.48, projected to increase to 0.56 in 2025, 0.72 in 2026, and 0.88 in 2027 [2]. Product Performance - The company reported a revenue of 3.45 billion from deceleration motors, a slight increase of 0.78%, while precision reducers generated 2.43 billion, up by 1.07%. However, the intelligent execution units saw a significant decline in revenue by 23.65% [3]. - The gross margin improved to 29.21%, reflecting a year-on-year increase of 4.24 percentage points, indicating effective cost management despite a slight revenue decline [3]. Market Position - The company is well-positioned in the rapidly growing humanoid robot market, with expectations of reaching one million units by 2027. The current global production capacity for harmonic reducers is insufficient to meet demand, suggesting a strategic advantage for the company as it expands production [9].

Investment Rating - The investment rating for the company is "Buy" (首次覆盖) [4][7] Core Views - The company is a leading player in the garment accessories sector, with solid capacity and product layout that strengthen its competitive advantage [4][7] - The Chinese garment accessories market is expected to maintain stable growth, with a projected CAGR of 5.03% from 2023 to 2030, reaching a market size of 129.16 billion yuan by 2030 [6][13] - The company has been focusing on overseas capacity expansion and product innovation to enhance operational efficiency and customer collaboration [9][31] Financial Performance and Forecast - Revenue and profit forecasts for the company are as follows: - 2023: Revenue of 3,907 million yuan, net profit of 558 million yuan - 2024: Revenue of 4,674 million yuan (up 19.66% YoY), net profit of 700 million yuan (up 25.48% YoY) - 2025: Revenue of 5,183 million yuan (up 10.89% YoY), net profit of 783 million yuan (up 11.80% YoY) - 2026: Revenue of 5,703 million yuan (up 10.02% YoY), net profit of 879 million yuan (up 12.33% YoY) - 2027: Revenue of 6,209 million yuan (up 8.88% YoY), net profit of 967 million yuan (up 9.95% YoY) [5][52] Market Dynamics - The company has established over 20 sales subsidiaries and more than 50 marketing outlets globally, enhancing its collaboration with leading apparel brands [30][31] - The company is committed to high-standard green smart factory construction, which has led to continuous improvements in operational efficiency [48][49] Research and Development - The company has invested significantly in R&D, with expenses reaching 181 million yuan in 2024, a 13.04% increase YoY, and holds 1,372 valid patents [44][50] - The company’s products have received multiple design awards, enhancing its competitive edge in the market [46][47] Competitive Positioning - The company is positioned as a top player in the garment accessories sector, benefiting from its operational efficiency, product innovation, and capacity growth [7][9] - Comparable companies in the same sector include Huayi Group and Anta Sports, which provide a benchmark for valuation [7][57]

[Table_Tag] [Table_Summary] 投资要点 证券研究报告·公司点评报告·电力设备 科润智控（834062） 证券分析师 朱洁羽 2024 年报&2025 一季报点评：25 年变压器需 求旺盛，公司业绩有望高增 买入（维持） | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 1,004 | 1,348 | 1,840 | 2,359 | 2,962 | | 同比（%） | 15.43 | 34.29 | 36.54 | 28.21 | 25.56 | | 归母净利润（百万元） | 73.03 | 42.86 | 84.44 | 123.08 | 168.03 | | 同比（%） | 26.47 | (41.31) | 97.00 | 45.76 | 36.53 | | EPS-最新摊薄（元/股） | 0.39 | 0.23 | 0.45 | 0.66 | 0.90 | | P/E（现价&最新摊薄） | 22. ...

证券研究报告·公司点评报告·医疗器械 2025 年 05 月 06 日 证券分析师 朱国广 执业证书：S0600520070004 zhugg@dwzq.com.cn 证券分析师 赵骁翔 执业证书：S0600524120003 九安医疗（002432） 2024 及 2025Q1 业绩点评：品牌渠道优势显 著，慢病 O+O 有望打开第二增长曲线 买入（维持） | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 3,231 | 2,592 | 2,809 | 3,468 | 3,542 | | 同比（%） | (87.72) | (19.77) | 8.37 | 23.46 | 2.13 | | 归母净利润（百万元） | 1,252 | 1,669 | 1,449 | 1,646 | 1,667 | | 同比（%） | (92.19) | 33.33 | (13.18) | 13.63 | 1.24 | | EPS-最新摊薄（元/股 ...

证券研究报告 | 公司深度 | 化学制品 嘉化能源(600273) 报告日期：2025 年 05 月 06 日 循环经济铸核心优势，分红回购并举强化股东回报 ——嘉化能源深度报告 报告导读 ❑ 嘉化能源以热电联产为核心，对外与嘉兴港区众多企业形成"资源-产品-再生资 源"的良性循环产业链；对内构建起包括基础化工、特色新材料、氢能源利用等 在内的能源和化工循环型产业体系，核心优势明显，经营稳中向上。同时，公司 重视股东回报，高分红与回购并举，股息率+回购注销率有望近 10%。 投资要点 ❑ 以热电联产为核心扩张多元化产品链，业务聚焦内需受关税影响较小 公司以热电联产为核心持续做好能力提升，一方面产业链条不断向高附加值延 伸，从热电到氯碱、再到脂肪醇等，构建循环型产业体系；另一方面，核心产品 持续扩能驱动成长。同时，公司各大业务聚焦国内市场，在国际贸易争端频发背 景下，公司受影响较小，有望实现稳健经营。 ❑ 依托嘉兴港区打造外循环，蒸汽业务稳步向上 热电联产具有较强政策及区域壁垒，作为嘉兴港区唯一一家蒸汽供热单位，公司 与园区众多化工企业形成"资源—产品—再生资源"的良性循环产业链，园区产 业经济持续向好也为公司 ...

社会服务 | 证券研究报告 — 调整盈利预测 2025 年 5 月 6 日 300860.SZ 增持 原评级：增持 市场价格:人民币 25.31 板块评级:强于大市 股价表现 (%) 今年 至今 1 个月 3 个月 12 个月 绝对 (9.3) (11.7) (7.8) (29.7) 相对深圳成指 (7.4) (5.0) (5.3) (33.0) 发行股数 (百万) 190.93 流通股 (百万) 111.90 总市值 (人民币 百万) 4,832.47 3 个月日均交易额 (人民币 百万) 146.90 主要股东 沙晓岚 42.13% (23%) (7%) 8% 23% 38% 53% May-24 Jun-24 Jul-24 Aug-24 Sep-24 Oct-24 Nov-24 Dec-24 Jan-25 Feb-25 Mar-25 Apr-25 锋尚文化 深圳成指 资料来源：公司公告， Wind ，中银证券 以 2025 年 4 月 30 日收市价为标准 相关研究报告 《锋尚文化》20240826 《锋尚文化》20231026 《锋尚文化》20230922 中银国际证券股份有限公司 具备证券投资咨询业 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is increasing its R&D investment and has initiated its first overseas registration clinical trial for its core product BL-B01D1 [7] - The company reported a significant decline in revenue and profit for Q1 2025, primarily due to the absence of large intellectual property licensing income that was recognized in the same period last year [7] - BL-B01D1 has over 40 ongoing clinical studies, with several in Phase III trials, indicating strong potential for becoming a standard treatment for various cancers [7] - The company forecasts revenues of 2.018 billion for 2025, with growth expected in subsequent years, reflecting the potential of its innovative products [7] Financial Summary - Total revenue for 2023 is projected at 561.87 million, with a significant increase to 5,822.72 million in 2024, followed by a decrease to 2,018 million in 2025 [1] - The net profit attributable to the parent company is expected to be a loss of 780.50 million in 2023, with a recovery to a profit of 3,707.51 million in 2024, followed by further losses in the subsequent years [1] - The latest diluted EPS is projected to be (1.95) in 2023, improving to 9.25 in 2024, but declining again in the following years [1]